home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 02/26/24

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - When the Price of (APRE) Talks, People Listen

2024-02-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
APRE - Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Invest...

APRE - Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President ...

APRE - Aprea Therapeutics files for $150M mixed shelf

2024-01-26 10:01:30 ET More on Aprea Therapeutics Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea Therapeutics Read the full article on Seeking Alpha For further...
APRE - Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting ...

APRE - Aprea Therapeutics GAAP EPS of -$0.86

2023-11-09 17:40:09 ET More on Aprea Therapeutics Aprea Therapeutics (APRE) Investor Presentation - Slideshow Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea Therapeutic...

APRE - Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the t...
APRE - Expected US Company Earnings on Wednesday, November 8th, 2023

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

APRE - Expected earnings - Aprea Therapeutics Inc.

Aprea Therapeutics Inc. (APRE) is expected to report $-1.08 for Q3 2023

APRE - Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tue...
Previous 10 Next 10